Caroline Charles,1 *Jean de la Rosette,2 *Mark Emberton3
1. Scilink Medical Writing, Saint-Pierre-d’Irube, France
2. Department of Urology, AMC University Hospital, Amsterdam, the Netherlands
3. Interventional Oncology, Division of Surgery and Interventional Science, University College Hospital, London, UK
*Correspondence to email@example.com and firstname.lastname@example.org
Disclosure: M. Emberton has provided consultancy services to and received research funding from AngioDynamics Inc., SonaCare Inc., Sophiris Inc., Trod Medical, GSK, and Sanofi; and provided training for AngioDynamics Inc., and SonaCare Inc. J. de la Rosette is a consultant for AngioDynamics Inc.
Support: Funding for this article was provided by AngioDynamics.
Citation: EMJ Urol 2015;3:90–102.